News
A NEW weight loss jab that only needs to be taken once monthly leads to “substantial weight loss”, according to early trials.
MariTide is designed to combine the effects of glucagon-like peptide-1 (GLP-1) receptor activation with glucose-dependent ...
In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...
What does the fracturing of vaccine advice and policy mean for the U.S. health care ecosystem? Will the potential head of the Centers for Disease Control ...
Swap steaks for spinach and you might watch the scale plummet. In a 16-week crossover study, overweight adults who ditched ...
23h
Zacks Investment Research on MSNVKTX Initiates Phase 3 Study on Obesity Candidate VK2735Viking Therapeutics VKTX announced that it has initiated the phase III VANQUISH program, evaluating the subcutaneous (SC) ...
W. Timothy Garvey, M.D., served as lead author in the clinical trial. A new combination drug therapy is showing extraordinary ...
Drugs such as Ozempic (a brand name for semaglutide) are showing promise for weight loss. Another medication in the same ...
Alternatives to weekly injections of weight-loss drugs may be on the way. A monthly dose of a new drug called MariTide helped ...
The once-monthly drug is still under study but could provide added convenience and another option for patients.
A new drug from California-based pharma company Amgen, which has concluded a phase II trial, shows promise as a powerful ...
Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results